Scarica l'app Stockscreener
3.22
0.31%
0.01
Dopo l'orario di chiusura:
3.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie
Arbutus Biopharma (NASDAQ:ABUS) Receives “Buy” Rating from HC Wainwright - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’ - Insider Monkey
Barclays PLC Purchases 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Provides 2025 Corporate and Financial Update - GlobeNewswire
Jane Street Group LLC Has $258,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Principal Financial Group Inc. Sells 12,352 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development (NASDAQ:ABUS) - Seeking Alpha
Geode Capital Management LLC Buys 135,442 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Barclays PLC Acquires 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
State Street Corp Increases Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
State Street Corp Purchases 1,472,652 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Position Boosted by XTX Topco Ltd - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $754,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma's SWOT analysis: hepatitis B focus drives stock potential - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Charles Schwab Investment Management Inc. Grows Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Charles Schwab Investment Management Inc. Purchases 831,663 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Large Shareholder Urges Warminster-based Arbutus to Seek Partners Instead of Selling More Stock - MSN
Intech Investment Management LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Here’s Why Arbutus (ABUS) Surged in Q3 - Yahoo Finance
Arbutus Biopharma's SWOT analysis: focus on CHB treatment drives stock outlook - Investing.com
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - The Bakersfield Californian
Arbutus Biopharma's HBV Trial Hits 50% Cure Rate; Major Investor Urges Strategic Partnership - StockTitan
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Arbutus Biopharma (STU:I9DN) 9-Day RSI : 39.19 (As of Dec. 01, 2024) - GuruFocus.com
Principal Financial Group Inc. Reduces Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat - Yahoo Finance
Arbutus Biopharma (FRA:I9DN) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Long-Term Debt & Capital Lease Obligation : €0.88 Mil (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat
HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo
Arbutus Biopharma to Showcase Innovations at Jefferies London Healthcare Conference - MyChesCo
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B - Yahoo Finance
Two Seas Capital LP Adjusts Stake in Arbutus Biopharma Corp - GuruFocus.com
Arbutus to Present at Jefferies London Healthcare Conference - Yahoo Finance
Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
HC Wainwright Has Negative Forecast for ABUS FY2024 Earnings - MarketBeat
HC Wainwright Expects Weaker Earnings for Arbutus Biopharma - Defense World
HC Wainwright Reaffirms “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma 8-K Filing: Financial Results and Corporate Presentation Update - Defense World
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript - Insider Monkey
Arbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024 - MyChesCo
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
1.44%
7.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):